scholarly journals Animal Models Used in Testing the Biocompatibility of the Dental Implant – A Review

Author(s):  
Diana Larisa ANCUŢA ◽  
Cristin COMAN ◽  
Diana Mihaela ALEXANDRU ◽  
Maria CRIVINEANU

In order to investigate the interaction between the bone and the dental implant, in vivo testsare performed in accordance with the biocompatibility requirements. As in vitro tests do not provide sufficient data on the quality of the implants, the animal models are used because they allow a complete assessment of all the factors involved in the osseointegration process.The aim of the paper is to provide data on the bone structure of animal species involved in dental research, highlighting the complexity of bone structure and osseointegration depending on the species. At the same time, the importance of selecting animal models is emphasized, in order to obtain the most accurate data for the development of dental implants and their use in humans. Following the research, essential data were obtained that helped to synthesize the bone characteristics of animals such as rats, rabbits, pigs, sheep or goats and relate them to the human bone skeleton. These data are useful in choosing an animal model when testing a new dental implant.

2021 ◽  
Vol 24 (2) ◽  
pp. 167-175
Author(s):  
E. I. Firkova

Periodontal research has developed very fast in the last two decades. Although at this stage of science a lot of genetic and molecular-based trials are performed in order to elucidate the complex etiology, pathophysiology, biofilm-host interactions and responses on genetic and cellular level, in vivo animal models are still used. In many ways, in vivo experiments are superior to in vitro tests when the dynamics of the immune-inflammatory nature of the periodontal disease and peri-implantitis and the specific healing of soft and hard tissues is concerned. Screening the efficacy, mechanisms of action and application of different biomaterials requires in vivo experiments, be-fore the data translation to clinical settings. A number of small animals like rodents and large species like dogs and nonhuman primates are involved in periodontal research. As live creatures are used, the design of the studies must be well defined, with regard to the type of the animals, most suitable for the tested hypothesis, observation period, sample size, study power, critical size defects, and specific testing sites.


2011 ◽  
Vol 2 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Himanshu Arora ◽  
Anil Nafria ◽  
Anup Kanase

ABSTRACT Development of an optimal interface between bone and orthopedic or dental implants has taken place for many years. In order to determine whether a newly developed implant material conforms to the requirements of biocompatibility, mechanical stability and safety, it must undergo rigorous testing both in vitro and in vivo. Results from in vitro studies can be difficult to extrapolate to the in vivo situation. For this reason the use of animal models is often an essential step in the testing of orthopedic and dental implants prior to clinical use in humans. This review discusses the reasons, the importance, and the research carried out in rabbits in our quest to develop a dental implant ideally suited for human bone.


1990 ◽  
Vol 18 (1_part_1) ◽  
pp. 19-22
Author(s):  
Marcel B. Roberfroid ◽  
Fabienne Goethals

Foreword — Animal experimentation is an emotional topic, which arouses passionate feelings both in animal protection groups and in the scientific community. For many years, antivivisectionists have fought for the abolition of all animal experimentation, whereas other groups campaign for suppression/reduction of the level of pain animals suffer because of experimentation. Despite all these efforts, the number of animals used in scientific research does not seem to have decreased significantly during the last few years. At best, this number remains constant or shows minor reductions in some countries, whereas in others it is still increasing. In addition to this situation, which certainly does not satisfy the antivivisectionists, the validity of the use of animal models in biomedical research is increasingly being questioned. On the other hand, a number of developments and projects exist which attest to the growing interest of scientists in in vitro models which use few, or even no, animals. Such a change in attitude is particularly evident in practice and research in toxicology, which uses a large number of animals. Taking into account the special status of toxicology among the biomedical sciences, since its practice is required and defined by laws and directives, a semantic problem exists over which adjective should be applied to describe such new methods. For some, it must be alternative — for consistancy to underline the possibility of replacing classical in vivo tests with new in vitro tests, the validity of which is demonstrated by reference to these in vivo tests. For others, it has to be complementary — to characterise the new protocols and the new experimental models which are of interest, because they contribute to the improvement of toxicology by strengthening its scientific nature. For a third group, it must be adjunct — to emphasise the relatively minor role of non-animal tests in relation to the conventional animal tests. It is the second concept that is favoured in this article. The experimental models to which it applies will, according to the Three Rs of Russell & Burch (1), lead either to the replacement of animal models, or to a reduction in the number of animals used or to refinement of test procedures in order to minimise the suffering and stress caused to animals.


2019 ◽  
Vol 64 (1) ◽  
pp. 43-50
Author(s):  
David Pammer

There are several types of primary and secondary stability measuring methods, but there are no calculating methods to determine direct primary stability. The aim of this work is to make a calculation method for primary stability. The out coming result of the calculation should be the same form and unit as available in the clinical and used RFA (Resonance Frequency Analysis) method, especially the ISQ (Implant Stability Quotient). Dental implant analog screws were inserted in bone modelling standard PUR (Polyurethane) solid foam blocks, and the insertion torque and the micromotion was monitored. The ISQ values of the inserted screws were measured also. On the basis of results, the characteristic equation was determined, which showed an excellent correlation (r = 0.96) between the micro mobility and ISQ. To simulate the micro mobility of an inserted screw with FEA (Finite Element Analysis) in any case of the change the bone material properties is not difficult instead of in vitro and in vivo examinations. Using the simulation results and the characteristic equation the clinically used ISQ value could be determinable. Thanks to this simple method, it is easy to monitor virtually the stability change in any lesion of bone structure. As a result of the conducted measurements and simulations, it can be concluded that the ISQ value, which represent the implant primary stability, can be calculated via FEA. With this simulation method, it is possible to predict and monitor pre-clinically the primary stability of dental implants with new geometries.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4175-4175
Author(s):  
Cesare Perotti ◽  
Paola Bergamaschi ◽  
Gianluca Viarengo ◽  
Claudia Del Fante ◽  
Laura Bellotti ◽  
...  

Abstract Introduction: Platelet concentrates (PC) collected by apheresis are effective in supporting deeply thrombocytopenic patients. The reduced risk of multiple allogeneic exposure and transmissible infectious diseases together with the high WBC depletion and diminished transfusion reactions are the main advantages offered by PC transfusion. At moment, the availability of several synthetic solutions for platelets storage permits to prepare hyperconcentrate(dry) apheresis platelets with the advantage of reducing febrile non-hemolytic transfusion reactions and, in low body weight patients the citrate toxicity, without the necessity of further manipulations. The aim of this study was to test the quality of 20 dry platelets (DP) in comparison to 20 standard plateletpheresis (SP) concentrates. Materials and methods: A total of 40 apheresis procedures were performed by the single-needle Cobe Trima separation device (Gambro BCT, Lakewood, CO, USA) collecting either DP or SP concentrates. Within 1h after collection, the bag containing DP was added with the appropriate amount (70% of DP final volume) of synthetic solution for platelets storage (SSP, MacoPharma). Both DP and SP concentrates were stored at room temperature with gentle agitation for 4 days. For both concentrates, platelet yield was calculated and in vitro studies of membrane glycoproteins expression and aggregation at day +1 and day +4 were carried out. Results: The comparison between 20 DP and 20 SP concentrates in terms of ability to aggregate in vitro and membrane glycoproteins expression at day +1 and day +4 of storage is reported in table A and B respectively. Conclusions: The in vitro tests documented a major activation of dry platelets. In particular, the ability to aggregate was reduced in the 20 DP concentrates analised and this phenomenon was more evident at day +4 of storage. The alteration of membrane glycoproteins expression (markers of storage lesion) confirms the lower in vitro quality of DP concentrates. The effectiveness of this new blood component in vivo should be evaluated in a controlled clinical trial. Table A. At collection Day +1 Day +4 SP DP SP DP SP DP Collagen μg/ml 4 93 88 97 82 80 53 ADP 10 μM 32 11 24 16 16 5 Ristocetin 1.5 mg/ml 91 97 77 81 71 52 Collagen 10 μg/ml + Adrenaline 10 μM 98 95 93 94 93 80 ADP 10 μM + Adrenaline 10 μM 87 72 76 61 57 30 Table B. At collection Day +1 Day +4 SP DP SP DP SP DP GPIb alfa (MFI) 5.06 5.75 6.31 6.13 5.26 4.54 GPIIb-IIIa (MFI) 35.47 36.71 34.61 37.7 31.76 40.9 GP IV (MFI) 11.49 11.4 11.67 10.28 11.65 11.38 GP 53 24.23 27.11 21.74 25.91 21.46 31.84 GMP 140 21.79 29.29 22.65 30.38 20.58 34.89


1991 ◽  
Vol 66 (05) ◽  
pp. 609-613 ◽  
Author(s):  
I R MacGregor ◽  
J M Ferguson ◽  
L F McLaughlin ◽  
T Burnouf ◽  
C V Prowse

SummaryA non-stasis canine model of thrombogenicity has been used to evaluate batches of high purity factor IX concentrates from 4 manufacturers and a conventional prothrombin complex concentrate (PCC). Platelets, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A (FPA) were monitored before and after infusion of concentrate. Changes in FPA were found to be the most sensitive and reproducible indicator of thrombogenicity after infusion of batches of the PCC at doses of between 60 and 180 IU/kg, with a dose related delayed increase in FPA occurring. Total FPA generated after 100-120 IU/kg of 3 batches of PCC over the 3 h time course was 9-12 times that generated after albumin infusion. In contrast the amounts of FPA generated after 200 IU/kg of the 4 high purity factor IX products were in all cases similar to albumin infusion. It was noted that some batches of high purity concentrates had short NAPTTs indicating that current in vitro tests for potential thrombogenicity may be misleading in predicting the effects of these concentrates in vivo.


1980 ◽  
Vol 44 (02) ◽  
pp. 081-086 ◽  
Author(s):  
C V Prowse ◽  
A E Williams

SummaryThe thrombogenic effects of selected factor IX concentrates were evaluated in two rabbit models; the Wessler stasis model and a novel non-stasis model. Concentrates active in either the NAPTT or TGt50 in vitro tests of potential thrombogenicity, or both, caused thrombus formation in the Wessler technique and activation of the coagulation system in the non-stasis model. A concentrate with low activity in both in vitro tests did not have thrombogenic effects in vivo, at the chosen dose. Results in the non-stasis model suggested that the thrombogenic effects of factor IX concentrates may occur by at least two mechanisms. A concentrate prepared from platelet-rich plasma and a pyrogenic concentrate were also tested and found to have no thrombogenic effect in vivo.These studies justify the use of the NAPTT and TGt50 in vitro tests for the screening of factor IX concentrates prior to clinical use.


1976 ◽  
Vol 36 (02) ◽  
pp. 401-410 ◽  
Author(s):  
Buichi Fujttani ◽  
Toshimichi Tsuboi ◽  
Kazuko Takeno ◽  
Kouichi Yoshida ◽  
Masanao Shimizu

SummaryThe differences among human, rabbit and guinea-pig platelet adhesiveness as for inhibitions by adenosine, dipyridamole, chlorpromazine and acetylsalicylic acid are described, and the influence of measurement conditions on platelet adhesiveness is also reported. Platelet adhesiveness of human and animal species decreased with an increase of heparin concentrations and an increase of flow rate of blood passing through a glass bead column. Human and rabbit platelet adhesiveness was inhibited in vitro by adenosine, dipyridamole and chlorpromazine, but not by acetylsalicylic acid. On the other hand, guinea-pig platelet adhesiveness was inhibited by the four drugs including acetylsalicylic acid. In in vivo study, adenosine, dipyridamole and chlorpromazine inhibited platelet adhesiveness in rabbits and guinea-pigs. Acetylsalicylic acid showed the inhibitory effect in guinea-pigs, but not in rabbits.


1963 ◽  
Vol 10 (01) ◽  
pp. 106-119 ◽  
Author(s):  
E Beck ◽  
R Schmutzler ◽  
F Duckert ◽  

SummaryInhibitor of kallikrein and trypsin (KI) extracted from bovine parotis was compared with ε-aminocaproic acid (EACA): both substances inhibit fibrinolysis induced with streptokinase. EACA is a strong inhibitor of fibrinolysis in concentrations higher than 0, 1 mg per ml plasma. The same amount and higher concentrations are not able to inhibit completely the proteolytic-side reactions of fibrinolysis (fibrinogenolysis, diminution of factor V, rise of fibrin-polymerization-inhibitors). KI inhibits well proteolysis of plasma components in concentrations higher than 2,5 units per ml plasma. Much higher amounts of KI are needed to inhibit fibrinolysis as demonstrated by our in vivo and in vitro tests.Combination of the two substances for clinical use is suggested. Therapeutic possibilities are discussed.


2019 ◽  
Vol 25 (36) ◽  
pp. 3872-3880 ◽  
Author(s):  
Marcel M. Bergmann ◽  
Jean-Christoph Caubet

Severe cutaneous adverse reactions (SCAR) are life-threatening conditions including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Diagnosis of causative underlying drug hypersensitivity (DH) is mandatory due to the high morbidity and mortality upon re-exposure with the incriminated drug. If an underlying DH is suspected, in vivo test, including patch tests (PTs), delayed-reading intradermal tests (IDTs) and in vitro tests can be performed in selected patients for which the suspected culprit drug is mandatory, or in order to find a safe alternative treatment. Positivity of in vivo and in vitro tests in SCAR to drug varies depending on the type of reaction and the incriminated drugs. Due to the severe nature of these reactions, drug provocation test (DPT) is highly contraindicated in patients who experienced SCAR. Thus, sensitivity is based on positive test results in patients with a suggestive clinical history. Patch tests still remain the first-line diagnostic tests in the majority of patients with SCAR, followed, in case of negative results, by delayed-reading IDTs, with the exception of patients with bullous diseases where IDTs are still contra-indicated. In vitro tests have shown promising results in the diagnosis of SCAR to drug. Positivity is particularly high when the lymphocyte transformation test (LTT) is combined with cytokines and cytotoxic markers measurement (cyto-LTT), but this still has to be confirmed with larger studies. Due to the rarity of SCAR, large multi-center collaborative studies are needed to better study the sensitivity and specificity of in vivo and in vitro tests.


Sign in / Sign up

Export Citation Format

Share Document